An agenda for Clinical Trials: clinical trials in the genomic era

1. Giaccone G , Herbst RS , Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777–784.

2. Herbst RS , Giaccone G , Schiller JH et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785–794.

3. Lynch TJ , Bell DW , Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.

4. Paez JG , Janne PA , Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.

5. Simon R , Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Can Res, in press.

6. Simon R , Korn E , McShane L , Radmacher M , Wright G , Zhao Y. Design and analysis of DNA microarray investigations. New York: Springer-Verlag, 2003.

7. Radmacher MD , McShane LM , Simon R. A paradigm for class prediction using gene expression profiles. J Computat Biol 2002; 9: 505–511.

8. Rosenwald A , Wright G , Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937–11947.

9. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Can 2003; 89: 1599–1604.

10. Mukherjee S , Tamayo P , Rogers S et al. Estimating dataset size requirements for classifying DNA microarray data. J Computat Biol 2003; 10: 119–142.

11. Dobbin K , Simon R. Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics, in press.

12. Hilsenbeck SG , Clark GM , McGuire WL . Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992; 22: 197–206.

13. Gasparini G , Pozza F , Harris AL . Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Nat Cancer Inst 1993; 85: 1206–1219.

14. Simon R , Altman DG . Statistical aspects of prognostic factor studies in oncology. Br J Can 1994; 69: 979–985.

15. Hayes DF , Trock B , Harris AL . Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Breast Cancer Res Treat 1998; 52: 304–319.

16. Simon R , Radmacher MD , Dobbin K , McShane LM . Pitfalls in the analysis of DNA microarray data: Class prediction methods. J Nat Cancer Inst 2003; 95: 14–18.

17. Simon R. When is a genomic classifier ready for prime time? Nat Clin Practice – Oncol, in press.